Prescription Drug SearchBrowse Alphabetically:
A
·
B
·
C
·
D
·
E
·
F
·
G
·
H
·
I
·
J
·
K
·
L
·
M
·
N
O
·
P
·
Q
·
R
·
S
·
T
·
U
·
V
·
W
·
X
·
Y
·
Z
·
#
Information about MyGlobalPharmacy.com
List of countries where we can ship Vancocin:
Latest news releases on Vancocin:
On December 14, 2011, the Company issued a press release announcing that as result of FDA approval of a supplemental new drug application, its drug Vancocin would enjoy three years of market exclusivity, and that generic Vancomycin capsules ...
The Company's main product is Vancocin, which is the brand name for Vancomycin, an antibiotic. The Complaint alleges that, on December 14, 2011, the Company issued a press release stating that it believed that Vancocin would have three years ...
In a suit filed in Pennsylvania federal court, the shareholder accuses the company of misleading investors with statements in December that its antibiotic brand, Vancocin, would qualify for three years of market exclusivity thanks to a new condition of use ...
On April 13, 2012, ViroPharma sued two federal agencies seeking a court order temporarily blocking approval of generic forms of its biggest product, the antibiotic Vancocin. Catalyst for Upward Movement ViroPharma's pipeline includes Cinryze (C1 esterase ...
Vancomycin (Vancocin) and meropenem (Merrem IV) also should be considered because of the high risk of coinfection with bacteria. Adjunctive therapies include minimization of immunosuppression, antimicrobial beads in open wounds, and negative-pressure wound ...
65% in 4Q11) from targeted hospitals is encouraging. Importantly, we continue to anticipate limited impact to DIFICID revenues from the recent introduction of generic Vancocin as a de-facto version (vancomycin slurry) was already present in the market.”
The treatment is a different type of antibiotic. The most commonly used are metronaidzole (Flagyl) and vancomycin (Vancocin) which are taken my mouth. Newer antibiotics have also been developed. What is worrisome is that there is an emerging new ...
65% in 4Q11) from targeted hospitals is encouraging. Importantly, we continue to anticipate limited impact to DIFICID revenues from the recent introduction of generic Vancocin as a de-facto version (vancomycin slurry) was already present in the market.”
On April 10, 2012, shares of ViroPharma common stock dropped $6.17, closing at $22.44 per share, after the Company announced that the FDA would not grant additional exclusivity for its drug Vancocin. This announcement stood in stark contrast to the ...